Can artificial intelligence redefine the future of drug development and clinical trials? 

In this episode of Tech Talks Daily, I sit down with Dave Latshaw, Ph.D., the internationally recognized AI and machine learning expert who serves as CEO of BioPhy. Founded in 2019, BioPhy focuses on using AI to revolutionize the later stages of drug development, a critical yet often overlooked segment of the pharmaceutical pipeline.

Dave shares insights into BioPhy’s innovative platform, which combines scientific, clinical, and regulatory insights to predict clinical trial success and steer capital allocation. At the heart of BioPhy’s approach is its patent-pending AI engine, BioLogic, and generative AI solution, BioPhyRx, designed to enhance clinical trial outcomes, reduce failure rates, and accelerate the time to market for life-saving drugs. Dave also explores how BioPhy’s operational assessment model prioritizes immediate ROI by addressing challenges downstream from drug discovery.

In our conversation, Dave delves into the complexities of AI adoption in pharma, including the challenges of scaling AI solutions, managing high computational costs, and overcoming stakeholder fears about job displacement. Drawing from his experience at Johnson & Johnson, where his AI innovations contributed to the global rollout of the COVID-19 vaccine, Dave reflects on lessons learned and the transformative potential of AI in healthcare.

As we look ahead, Dave discusses the future of AI in reducing administrative burdens on clinicians, automating regulatory compliance, and enabling groundbreaking advancements like DeepMind’s AlphaFold. 

How can AI transform not just how we develop drugs but also the healthcare outcomes for millions of people worldwide? Tune in to find out, and share your thoughts on the role of AI in the future of medicine.